EP2714074A4 - Anticorps anti-emr1 - Google Patents

Anticorps anti-emr1

Info

Publication number: EP2714074A4
Authority: EP; European Patent Office
Prior art keywords: emr1; antibodies; emr1 antibodies
Prior art date: 2011-05-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP12792379.5A

Other languages

German (de)

English (en)

Other versions

EP2714074A2 (fr

Inventor

Kenneth Luehrsen

Mark Baer

Christopher Bebbington

David Martinez

Varghese Palath

Swathi Sujatha-Bhaskar

Nenad Tomasevic

Jason Williams

Geoffrey Yarranton

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Humanigen Inc

Original Assignee

Kalobios Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-27

Filing date

2012-05-25

Publication date

2015-04-22

2012-05-25 Application filed by Kalobios Pharmaceuticals Inc filed Critical Kalobios Pharmaceuticals Inc

2014-04-09 Publication of EP2714074A2 publication Critical patent/EP2714074A2/fr

2015-04-22 Publication of EP2714074A4 publication Critical patent/EP2714074A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Dermatology (AREA)
Neurology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

EP12792379.5A 2011-05-27 2012-05-25 Anticorps anti-emr1 Withdrawn EP2714074A4 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161491095P	2011-05-27	2011-05-27
PCT/US2012/039717 WO2012166659A2 (fr)	2011-05-27	2012-05-25	Anticorps anti-emr1

Publications (2)

Publication Number	Publication Date
EP2714074A2 EP2714074A2 (fr)	2014-04-09
EP2714074A4 true EP2714074A4 (fr)	2015-04-22

Family

ID=47260230

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP12792379.5A Withdrawn EP2714074A4 (fr)	2011-05-27	2012-05-25	Anticorps anti-emr1

Country Status (7)

Country	Link
US (1)	US9045539B2 (fr)
EP (1)	EP2714074A4 (fr)
JP (1)	JP2014523867A (fr)
CN (1)	CN103747801A (fr)
AU (1)	AU2012262465A1 (fr)
CA (1)	CA2836947A1 (fr)
WO (1)	WO2012166659A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2599423C1 (ru) *	2015-07-28	2016-10-10	Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран)	Рекомбинантные однодоменные антитела, специфически связывающие белок f4/80, способ их получения и использования для детекции этого белка
CN114908165A (zh) *	2022-04-11	2022-08-16	浙江大学	急性髓性白血病诊断和治疗的生物标记物及其应用
WO2025188923A1 (fr) *	2024-03-07	2025-09-12	China Medical University	Anticorps pour traiter la polyarthrite rhumatoïde et son utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5714350A (en) *	1992-03-09	1998-02-03	Protein Design Labs, Inc.	Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU2002332290B2 (en)	2001-09-25	2007-11-08	Astellas Pharma Inc.	Recombinant anti-osteopontin antibody and use thereof
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
US7232337B1 (en) *	2006-03-13	2007-06-19	Tyco Electronics Corporation	Connector receptacle assembly

2012
- 2012-05-25 JP JP2014512166A patent/JP2014523867A/ja active Pending
- 2012-05-25 CN CN201280037469.1A patent/CN103747801A/zh active Pending
- 2012-05-25 AU AU2012262465A patent/AU2012262465A1/en not_active Abandoned
- 2012-05-25 US US13/480,937 patent/US9045539B2/en active Active
- 2012-05-25 EP EP12792379.5A patent/EP2714074A4/fr not_active Withdrawn
- 2012-05-25 WO PCT/US2012/039717 patent/WO2012166659A2/fr not_active Ceased
- 2012-05-25 CA CA2836947A patent/CA2836947A1/fr not_active Abandoned

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JÖRG HAMANN ET AL: "EMR1, the human homolog of F4/80, is an eosinophil-specific receptor", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 37, no. 10, 1 October 2007 (2007-10-01), pages 2797 - 2802, XP055152218, ISSN: 0014-2980, DOI: 10.1002/eji.200737553 *

Also Published As

Publication number	Publication date
CN103747801A (zh)	2014-04-23
AU2012262465A1 (en)	2013-12-12
EP2714074A2 (fr)	2014-04-09
WO2012166659A2 (fr)	2012-12-06
CA2836947A1 (fr)	2012-12-06
WO2012166659A3 (fr)	2013-03-21
US20130064826A1 (en)	2013-03-14
JP2014523867A (ja)	2014-09-18
US9045539B2 (en)	2015-06-02

Publication	Publication Date	Title
IL272035A (en)	2020-02-27	Anti IL–36R antibodies
IL259826A (en)	2018-07-31	Anti-alphabetatisiar antibody
IL264558A (en)	2019-02-28	Anti–il–23p19 antibodies
GB201103955D0 (en)	2011-04-20	Antibodies
GB201112056D0 (en)	2011-08-31	Antibodies
ZA201307983B (en)	2016-01-27	Anti-b7-h3 antibody
IL235042A0 (en)	2014-12-31	Anti–fcrn antibodies
IL234848A0 (en)	2014-12-31	Protease controlled antibodies
IL236259A0 (en)	2015-02-26	Anti 15–siglec antibodies
SG10201709290XA (en)	2018-01-30	Anti-H7cr Antibodies
TWI563004B (en)	2016-12-21	Anti-hxcr1 antibody
EP2714074A4 (fr)	2015-04-22	Anticorps anti-emr1
GB201116342D0 (en)	2011-11-02	Antigen combinations
IL235188A0 (en)	2014-12-31	Antibodies against c-pdgf

Legal Events

Date	Code	Title	Description
2014-03-07	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2014-04-09	17P	Request for examination filed	Effective date: 20131219
2014-04-09	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2014-09-03	DAX	Request for extension of the european patent (deleted)
2014-12-24	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101ALI20141120BHEP Ipc: A61K 39/00 20060101AFI20141120BHEP Ipc: A61K 39/395 20060101ALI20141120BHEP
2015-04-22	A4	Supplementary search report drawn up and despatched	Effective date: 20150320
2015-04-22	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/395 20060101ALI20150316BHEP Ipc: A61K 39/00 20060101AFI20150316BHEP Ipc: C07K 16/28 20060101ALI20150316BHEP
2017-03-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2017-04-26	18D	Application deemed to be withdrawn	Effective date: 20161201